Necroptosis pathways in tumorigenesis. (November 2022)

• Record Type: Journal Article
• Authors: Zhang, Tao; Wang, Yingnan; Inuzuka, Hiroyuki; Wei, Wenyi
• Is Part Of: Seminars in cancer biology. Volume 86(2023)Part 3
• Page Start: 32
• Page End: 40
• Publication Date: 2022-11
• Subjects: Necroptosis -- RIPK1 -- RIPK3 -- Inflammation -- Tumorigenesis; Cancer -- Periodicals; Neoplasms -- Periodicals; Review Literature; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.semcancer.2022.07.007
• Languages: English
• ISSNs: 1044-579X

Abstract

Abstract: Necroptosis is a caspase-independent form of programmed cell death executed by the receptor interacting protein kinase 1 (RIPK1)-RIPK3-mixed lineage kinase domain-like protein (MLKL) signaling cascade, deregulation of which can cause various human diseases including cancer. Escape from programmed cell death is a hallmark of cancer, leading to uncontrolled growth and drug resistance. Therefore, it is crucial to further understand whether necroptosis plays a key role in therapeutic resistance. In this review, we summarize the recent findings of the link between necroptosis and cancer, and discuss that targeting necroptosis is a new strategy to overcome apoptosis resistance in tumor therapy.